These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10429808)

  • 1. [Vaccines against respiratory syncytial virus].
    Freymuth F; Vabret A; Gouarin S; Gueudin M; Petitjean J
    Arch Pediatr; 1999; 6 Suppl 3():650s-654s. PubMed ID: 10429808
    [No Abstract]   [Full Text] [Related]  

  • 2. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.
    Delgado MF; Polack FP
    Expert Rev Vaccines; 2004 Dec; 3(6):693-700. PubMed ID: 15606354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New vaccines against mucosal pathogens: rotavirus and respiratory syncytial virus.
    Coffin SE; Offit PA
    Adv Pediatr Infect Dis; 1997; 13():333-48. PubMed ID: 9544318
    [No Abstract]   [Full Text] [Related]  

  • 4. Prospects for a respiratory syncytial virus vaccine.
    Hall CB
    Science; 1994 Sep; 265(5177):1393-4. PubMed ID: 7915433
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.
    Piedra PA; Wyde PR; Castleman WL; Ambrose MW; Jewell AM; Speelman DJ; Hildreth SW
    Vaccine; 1993 Nov; 11(14):1415-23. PubMed ID: 7508665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus: reverse genetics and vaccine strategies.
    Collins PL; Murphy BR
    Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
    [No Abstract]   [Full Text] [Related]  

  • 7. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
    Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR
    J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current progress on development of respiratory syncytial virus vaccine.
    Chang J
    BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine.
    Welliver RC; Tristram DA; Batt K; Sun M; Hogerman D; Hildreth S
    J Infect Dis; 1994 Aug; 170(2):425-8. PubMed ID: 8035030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of respiratory syncytial virus infection in a peripheral hospital: economic problems and ethical questions].
    Faverge B; Bonein M; Attou D; Benskhria S; Gratecos L
    Arch Pediatr; 2000 Apr; 7(4):429. PubMed ID: 10793937
    [No Abstract]   [Full Text] [Related]  

  • 15. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in and the potential of vaccines for respiratory syncytial virus.
    Jorquera PA; Oakley KE; Tripp RA
    Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein conformation in a vaccine matters.
    Morrison TG
    Oncotarget; 2015 Sep; 6(26):21781-2. PubMed ID: 26318167
    [No Abstract]   [Full Text] [Related]  

  • 20. Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia.
    Shi X; Zheng J; Yan T
    J Mol Model; 2018 Mar; 24(4):79. PubMed ID: 29500665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.